PROHANCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prohance, and when can generic versions of Prohance launch?
Prohance is a drug marketed by Bracco and is included in two NDAs.
The generic ingredient in PROHANCE is gadoteridol. Two suppliers are listed for this compound. Additional details are available on the gadoteridol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prohance
A generic version of PROHANCE was approved as gadoteridol by HAINAN POLY on February 11th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PROHANCE?
- What are the global sales for PROHANCE?
- What is Average Wholesale Price for PROHANCE?
Summary for PROHANCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Clinical Trials: | 9 |
| Patent Applications: | 740 |
| Drug Prices: | Drug price information for PROHANCE |
| What excipients (inactive ingredients) are in PROHANCE? | PROHANCE excipients list |
| DailyMed Link: | PROHANCE at DailyMed |
Recent Clinical Trials for PROHANCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alabama at Birmingham | Early Phase 1 |
| University of Alabama at Birmingham | Phase 1 |
| Guerbet | Phase 4 |
Pharmacology for PROHANCE
| Drug Class | Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for PROHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bracco | PROHANCE MULTIPACK | gadoteridol | INJECTABLE;INJECTION | 021489-001 | Oct 9, 2003 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PROHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PROHANCE
See the table below for patents covering PROHANCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1296715 | 1-(SUBSTITUANT)-1,4,7-TRIS(CARBOXYMETHYL)-1,4,7,10- TETRAAZACYCLODODECANE ET COMPOSES ANALOGUES (1-SUBSTITUTED-1,4,7-TRISCARBOXYMETHYL-1,4,7,10- TETRAAZACYCLODODECANE AND ANALOGS) | ⤷ Start Trial |
| Germany | 3772785 | ⤷ Start Trial | |
| Germany | 3855451 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch